首页> 外文期刊>ACS medicinal chemistry letters >Academic Drug Development: The DRIVE Model
【24h】

Academic Drug Development: The DRIVE Model

机译:学术药物开发:驱动模型

获取原文
获取原文并翻译 | 示例
           

摘要

Although there are hundreds of academic drug discovery centers open around the world, there are comparatively few academic drug development centers that contain the key core competencies needed to progress a lead compound into clinical trials. This is largely a consequence of operating in the “Valley of Death” (i.e., insufficient infrastructure, expertise, and funding). We have created an academic drug development center called DRIVE (Drug Innovation Ventures at Emory) that was designed to overcome many of the intrinsic and occasionally unintended barriers associated with academic drug development. Herein, we report a proof of concept that the DRIVE model provides a robust framework for pursuing university-based drug development, especially when the drugs in question target rare and neglected diseases.
机译:虽然全世界有数百个学术药物发现中心,但有很少的学术药物开发中心,其中包含进展铅化合物进入临床试验所需的关键核心竞争力。 这主要是在“死亡谷”(即,基础设施不足,专业知识和资金不足)的后果。 我们创建了一个名为Drive(埃默里的药物创新企业)的学术药物开发中心,旨在克服与学术药物发展相关的许多内在和偶尔意外的障碍。 在此,我们报告了驱动模型为追求基于大学的药物开发提供了强大的框架的概念证明,特别是当有问题的药物患有罕见和被忽视的疾病时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号